Anavex Life Sciences Corp.

Equities

AVXL

US0327973006

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:04 2024-04-23 pm EDT			5-day change	1st Jan Change
3.68 ^USD	0.00%		-10.68%	-60.47%

Mar. 18	Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia	CI
Feb. 07	Transcript : Anavex Life Sciences Corp., Q1 2024 Earnings Call, Feb 07, 2024

Anavex Life Sciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022

May 10, 2022 at 07:00 am EDT

Anavex Life Sciences Corp. reported earnings results for the second quarter and six months ended March 31, 2022. For the second quarter, the company reported net loss was USD 10.44 million compared to USD 8.16 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.12 a year ago.
For the six months, net loss was USD 21.32 million compared to USD 16.01 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.24 a year ago.

Latest news about Anavex Life Sciences Corp.

Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia	Mar. 18	CI
Transcript : Anavex Life Sciences Corp., Q1 2024 Earnings Call, Feb 07, 2024	Feb. 07
Anavex Life Sciences Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 07	CI
North American Morning Briefing : Stock Futures -2-	Feb. 07	DJ
Anavex Life Sciences Initiates Phase 2 Trial of Schizophrenia Therapy	Jan. 17	MT
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of Anavex®3-71 in Schizophrenia	Jan. 16	CI
Transcript : Anavex Life Sciences Corp. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 10:30 AM	Jan. 11
Anavex Life Sciences Corp. Provides an Update on Rett Syndrome Program	Jan. 02	CI
Anavex Life Sciences Corp. Announces First Entire Clinical Gene Pathway Data of Anavex®2-73 from Avatar Study in Patients with Rett Syndrome	Dec. 20	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Dec. 19	MT
Sector Update: Health Care Stocks Gain in Afternoon Trading	Dec. 19	MT
Anavex Life Sciences Shares Rise on European Approval of Marketing Application for Oral Blarcamesine in Alzheimer's	Dec. 19	MT
Anavex Life Sciences Corp. Receives Agreement from the Committee for Medicinal Products for Human Use for the Submission of A Marketing Authorisation Application of Oral Blarcamesine for Alzheimer's Disease	Dec. 19	CI
Transcript : Anavex Life Sciences Corp., 2023 Earnings Call, Nov 27, 2023	Nov. 27
Anavex Life Sciences Corp. Reports Earnings Results for the Full Year Ended September 30, 2023	Nov. 27	CI
Anavex Life Sciences Corp. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	Nov. 27	CI
North American Morning Briefing : Stock Futures -2-	Nov. 27	DJ
MORNING BID AMERICAS-Stocks stall after VIX hits pre-COVID low	Nov. 27	RE
Anavex Life Sciences Secures New Patent for Insomnia, Anxiety Treatment	Nov. 22	MT
Anavex Life Sciences Begins European Marketing Authorization Process for Blarcamesine to Treat Alzheimer's Disease	Nov. 20	MT
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer?s Disease to European Medicines Agency	Nov. 20	CI
Anavex Life Sciences Corp. Appoints David Goldberger as Senior Vice President Regulatory Affairs	Nov. 06	CI
Anavex Life Sciences Corp. Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX(R) 3-71 to Prevent Cognitive Decline in Alzheimer's Disease	23-10-25	CI
Sector Update: Health Care Stocks Mixed Premarket Thursday	23-09-14	MT
Anavex Life Sciences Says Early Study of Blarcamesine Candidate Showed 'Significant Slowing' in Cognitive Decline in Alzheimer's Patients	23-09-14	MT

Chart Anavex Life Sciences Corp.

Duration

Period

More charts

Company Profile

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimerâs disease, Parkinsonâs disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Companyâs product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.68 USD

Average target price

40 USD

Spread / Average Target

+986.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANAVEX LIFE SCIENCES CORP.	-60.47%	302M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+1.66%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-6.82%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs